Currently available tools for early diagnosis and prognosis of prostate cancer lack sufficient accuracy. There is a need to identify novel biomarkers for this common malignancy. SOX family genes play an important role in embryogenesis and are also implicated in various cancers. SOX11 has been recently recognized as a potential tumour suppressor that is downregulated in prostate cancer. We hypothesized that hypermethylation may be responsible for SOX11 silencing in human prostate cancer. The aim of the study was to investigate SOX11 promoter methylation in prostate adenocarcinoma by comparing it with benign prostatic hyperplasia (BPH). A total of 143 human prostate tissue samples, 62 from patients with prostate cancer and 81 from patients with BPH were examined by methylation-specific PCR. Associations between SOX11 promoter methylation and clinicopathological parameters were assessed by univariate statistics. Detection rates of SOX11 promoter methylation were 80.6% and 35.8% in prostate cancer and BPH respectively (P < 0.001). SOX11 hypermethylation was associated with adverse clinicopathological characteristics of prostate cancer, including higher PSA level (P < 0.01), Gleason score ≥ 7 (P = 0.03) and perineural invasion (P = 0.03). SOX11 methylation was positively correlated with the PSA level (P = 0.001). Our data indicated that SOX11 can be a promising methylation marker candidate for differential diagnosis and risk stratification for prostate cancer.
Prostate cancer is the most common malignancy in men of the Western world (Ferlay et al. 2013) . Even though the incidence and mortality of prostate cancer are lower in the Asian population, it is still among the top five leading cancers in Asia (Bashir 2015) . Early detection is a key strategy to prevent high mortality rate of prostate carcinoma. Serum prostate-specific antigen (PSA) and digital rectal examination are widely adopted as the first line of active screening. For suspected individuals, prostate biopsy is then performed to acquire histopathological diagnosis using the Gleason grading system (Humphrey 2004) .
Neither PSA nor prostate biopsy has optimal performance. PSA testing has low positive predictive value, while the biopsy is prone to sampling errors and associated with false-negative rate (Hern andez & Thompson 2004; Greene et al. 2009 ). Overall, a high sensitivity of routine prostate cancer screening will allow for early diagnosis, but its low specificity increases the probability of having unnecessary biopsies and overtreatment (Pan et al. 2013) . One more challenge in prostate cancer management is that distinction between indolent and aggressive tumours is not clearly established, because currently employed prognostic factors such as serum PSA level, Gleason score and TNM stage have limited accuracy (Kristensen et al. 2014) .
Novel biomarkers of diagnostic and prognostic significance are thus very much needed. In addition, any new molecular markers of prostate cancer could also be considered as potential therapeutic targets. One group of markers that has attracted recent interest are the SOX transcription factors, also known as the sex-determining region Y (SRY) box family, comprise more than 20 highly conserved members playing an important role in embryogenesis (Wilson & Koopman 2002) . SOX genes were studied in various malignancies, where they could serve as tumour suppressors or promoters, depending on the tumour type and transcription factor studied (Castillo & Sanchez-Cespedes 2012) . Recently, SOX11 attracted wide attention after recognizing its diagnostic and prognostic significance in mantle cell lymphoma (Mozos et al. 2009; Nygren et al. 2012) . SOX11 plays an important role in the development of the neural system (Hyodo-Miura et al. 2002; Wang et al. 2013) . Several functional and clinicopathological studies demonstrated that SOX11 acts as a tumour suppressor in solid cancers (Hide et al. 2009; Sernbo et al. 2011; Zhang et al. 2013; Xu et al. 2015) . Yao et al. (2015) reported downregulation of SOX11 in prostate adenocarcinoma tissue compared to benign prostatic hyperplasia (BPH). They also established a SOX11 overexpression model and found a tumour suppressor role of the gene in prostate cancer cells (Yao et al. 2015) . So far there are no confirmational studies on SOX11 in prostate tumours.
A possible mechanism of SOX11 inhibition in prostate adenocarcinoma is due to methylation of the gene promoter. Hypermethylation of the promoter region of the tumour suppressor and DNA repair genes is an established mechanism of permanent gene silencing in malignant tumours (Baylin & Jones 2011) . Single-gene and genomewide epigenetic studies identified numerous targets affected by aberrant promoter methylation in prostate cancer (Park 2015; McKee & Tricoli 2015) . Some of them, such as APC, GSTP1 and PTGS2, were suggested as diagnostic tools to distinguish between normal and prostate cancer tissue (Goering et al. 2012; Richiardi et al. 2009; Yoon et al. 2012) . Interestingly, aberrant promoter hypermethylation occurs in prostate cancer earlier in the disease course and more consistently than recurrent somatic mutations (Strand et al. , 2015 . Methylation markers are promising tools for diagnosis, prognosis and targeted treatment of neoplasia.
Promoter methylation of SOX11 has been studied in several cancers such as hematopoietic malignancies (Gustavsson et al. 2010) , ovarian cancer (Sernbo et al. 2011) , gastric cancer (Xu et al. 2015) and nasopharyngeal carcinoma , but not in prostate cancer cells or tissues. Therefore, we aimed to investigate SOX11 promoter methylation in prostate adenocarcinoma and BPH with an emphasis on differential diagnosis between these lesions. In addition, we evaluated for the first time the clinicopathological significance of SOX11 methylation status in patients with prostate cancer.
Materials and methods

Patients and tissue samples
A total of 143 FFPE prostate tissue samples diagnosed at the Department of Pathology, King Chulalongkorn Memorial Hospital, during the 2006-2013 study period, were examined. Prostate cancer specimens were obtained from 62 patients during an open retropubic radical prostatectomy. None of these patients received hormonal treatment, chemotherapy or pre-operative radiotherapy. The control group included 81 samples of BPH excised during the transurethral resection of the prostate. Pathology reports were retrieved from the hospital database, and baseline clinical characteristics of the patients were recorded. All histological slides were reviewed by one pathologist with expertise in urologic pathology (PC) to maintain consistency of the diagnoses and to select blocks for molecular study.
DNA extraction and bisulphite treatment
Ten formalin-fixed, paraffin-embedded sections (5-10 lm thick) were obtained from each representative block for DNA extraction. Genomic DNA was extracted using QIAamp DNA FFPE Tissue Kit (Qiagen, CA, USA) following the instruction manual. In brief, after deparaffinization with xylene and washing with ethanol, the prostate tissue samples were incubated with proteinase K and treated with manufacturer's buffers. The isolated genomic DNA was eluted, measured with NanoDrop 2000c spectrophotometer (Thermo Fisher Scientific, CA, USA) and then used for bisulphite treatment.
Bisulphite modification of the genomic DNA was performed using EZ DNA Methylation-Gold Kit (Zymo Research, USA) according to the manufacturer's protocol. CT conversion reagent was prepared by mixing 900 ll of water, 50 ll of M-Dissolving Buffer and 300 ll of M-Dilution. Each reaction contained 130 ll of CT conversion reagent and 20 ll of genomic DNA. The temperature profile of the bisulphite treatment was as follows: 98°C for 10 min, 64°C for 2.5 h, then holding the bisulphite-treated DNA product at 4°C overnight and finally storing at À20°C until analysed.
Primer design and methylation-specific PCR
A set of primers for SOX11 gene promoter was designed using METHPRIMER, an open-access software (Li & Dahiya 2002) . After analysing 2000-bp region upstream of the transcription start site (SOX11 promoter region), four CpG islands were identified ( Figure 1a ). Based on the previous report, the nearest from the transcription start site CpG island was selected ( Figure 1b) (Gustavsson et al. 2010) . Primers for methylation reaction were 5 0 -ATTTTAATTTTTT-GTAGAAGGAGCG-3 0 (forward) and 5 
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Results
Baseline characteristics of the patients are summarized in Table 1 . Mean age of the patients with BPH was higher than that of the prostate cancer group (P < 0.001). Patients with prostate carcinoma had a higher level of PSA (P < 0.001) and heavier prostate weight (P < 0.001) compared to BPH patients. Biochemical recurrence was documented in 19 patients with cancer (31%) within a median follow-up period of 60 months.
The frequency of SOX11 promoter methylation in prostate carcinoma and BPH tissues is shown in Table 2 . Methylation and unmethylation bands were detected at 124 bp and 133 bp respectively (Figure 2 ). SOX11 promoter methylation was found in 80.6% cases of prostate cancer and 35.8% cases of BPH, and the difference between prostate cancer and BPH was statistically significant (P < 0.001, Fisher's exact test; Table 2 ). Interestingly, around 10% of the cases from each group demonstrated partial methylation, which means that both the methylated and unmethylated bands were present (Figure 2) . Partial methylation within a single CpG island is likely due to the difference in methylation among alleles, or among CpG sites within the given island (Turker et al. 1989) . For statistical analysis, cases of partial and complete methylation were combined.
To determine the association between SOX11 promoter methylation and clinicopathological parameters in patients with prostate cancer, a correlation analysis was performed. There was a statistically significant correlation between SOX11 methylation and markers of tumour aggressiveness, such as high Gleason score (≥7), perineural invasion and PSA level ≥ 20 ng/ml (Table 3) . Patients with SOX11-methylated tumours had higher levels of pre-operative PSA (median 12.1 ng/ml) than SOX11-unmethylated tumours (median 6.7 ng/ml; P = 0.01; Figure 3 ). Furthermore, SOX11 methylation was positively correlated with the PSA level (P = 0.001, chi-square test for trend). No correlation was found between SOX11 methylation and age, surgical 
Discussion
This study showed for the first time that promoter methylation of SOX11 was significantly more frequent in prostate adenocarcinoma compared to BPH. Moreover, SOX11 hypermethylation was associated with adverse clinicopathological characteristics of prostate cancer, including high Gleason score, perineural invasion and increased PSA level. Our findings indicated that SOX11 methylation may potentially be used for differential diagnosis and risk stratification for prostate cancer. DNA methylation of the promoter region is a common mechanism of gene silencing mediated by the inability of activating transcription factors to bind a promoter (Baylin & Jones 2011) . Aberrant DNA methylation patterns are described in various human tumours and recently have emerged as diagnostic and prognostic biomarkers (Baylin & Jones 2011) . Monitoring methylation patterns has been employed to detect cancer cells in clinical specimens such as tissue biopsies or body fluids. In addition to the diagnostic utility of methylation markers, epigenetic drugs are promising anticancer agents that can revert the aberrant gene expression in cancer cells, and to re-establish normal molecular signalling.
DNA methylation for cancer detection has some advantages over other molecular tools because of the inherent stability of DNA compared with RNA or protein (Yoon et al. 2012) . Various techniques were developed to study DNA methylation. These include methylation-specific PCR, nested Figure 2 Methylation-specific PCR analysis of the SOX11 promoter. Prostate cancer (upper panel, PCa) and benign prostate hyperplasia (lower panel, BPH) samples aligned against the ladder (lane 1), positive (P) and negative (N) controls. PCa1, PCa2, PCa3 and BPH1 showed SOX11 methylation, and PCa4, BPH3 and BPH4 exhibited SOX11 unmethylation, while BPH2 was partially methylated. M indicates the presence of methylated DNA (124 bp) and U unmethylated DNA (133 bp). Median PSA level in unmethylation and methylation groups was 6.7 ng/ml and 12.1 ng/ml respectively. Differences between the levels were evaluated using the Mann-Whitney U-test. *indicate outlier values.
two-stage PCR, quantitative methylation-specific PCR, liquid chromatography, DNA sequencing and pyrosequencing (Huang et al. 2013) . We chose methylation-specific PCR for this study because it is simple, accurate and easy to reproduce and is a cost-effective assay, which continues to be one of the most widely used techniques in epigenetics (Huang et al. 2013) . SOX family genes regulate specification and differentiation of various tissues during embryogenesis (Wilson & Koopman 2002) . SOX transcription factors may interplay with several signalling pathways during cancer development (Castillo & Sanchez-Cespedes 2012) . Several members of the SOX family have been implicated in prostate carcinogenesis. SOX2, SOX4 and SOX9 demonstrated tumour-promoting role in functional and clinicopathological studies (Zhong et al. 2012; Weina & Utikal 2014; Bilir et al. 2016) . SOX7 and SOX10 appear to have tumour suppressor properties, and both were found to be downregulated in aggressive prostate cancer (Zhong et al. 2012) .
While SOX11 has been recently recognized as a functional player in several malignancies (Mozos et al. 2009; Gustavsson et al. 2010; Sernbo et al. 2011) , its role in prostate carcinoma is largely unknown. The only available experimental study suggested the potential tumour suppressor function of SOX11 in prostate carcinoma cell lines (Yao et al. 2015) . The authors also found significant downregulation of SOX11 and low protein expression in tissue specimens (Yao et al. 2015) . We hypothesized that epigenetic mechanism may be responsible for SOX11 silencing in human prostate cancer. Our results showed that promoter hypermethylation is significantly more frequent in prostate cancer compared to BPH. Yao et al. reported positive SOX11 immunostaining in 17% of the prostate cancer vs. 82% of the BPH specimens. In addition, mRNA expression of SOX11 in BPH was more than three times higher than in adenocarcinoma (Yao et al. 2015) . Our findings on SOX11 promoter methylation status (81% of cancer vs. 36% of BPH) are consistent with the results of Yao et al. We speculate that promoter methylation is responsible for downregulation of SOX11 in prostate cancer. Reactivation of this tumour suppressor gene potentially can be achieved using therapeutic agents with the epigenetic mechanism.
It should be noted that utility of SOX11 as a single marker able to differentiate prostate cancer and BPH is limited. For instance, SOX11 methylation has a false-positive rate of 36% with regard to detection of cancer. This finding of low specificity is well acknowledged in the studies on prostate cancer, and PSA testing with its low specificity is the best example (Hern andez & Thompson 2004) . We believe that diagnostic potential of SOX11 can be employed in biomarker panels by combining with other methylation or molecular markers for prostate cancer (Pan et al. 2013; Strand et al. 2014) . Considering potential utility of SOX11 methylation as an early screening tool, there was no statistically significant difference between the group of BPH patients with PSA level < 4 ng/ml and ≥4 ng/ml (P = 0.14, Fisher's exact test). This finding is not surprising given that SOX11 is likely involved in the late steps of prostate cancer progression (Yao et al. 2015) .
Clinicopathological correlation in the cohort of patients with prostate cancer found that SOX11 methylation was associated with high PSA level and demonstrated positive correlation with the PSA concentration. Patients with SOX11-methylated tumours displayed almost double the levels of pre-operative PSA than those with SOX11-unmethylated tumours. We also found that SOX11 methylation was associated with Gleason score ≥ 7. Both PSA level and Gleason grading score are key elements of the risk stratification schemes for prostate cancer, which are necessary to predict biochemical recurrence (Patel et al. 2007; Greene et al. 2009 ). Furthermore, SOX11 methylation correlated with perineural invasion in our cohort. It is in concordance with the overexpression model, which demonstrated that invasive properties of prostate cancer cells are maintained by the downregulated SOX11 (Yao et al. 2015) . PSA level, Gleason score and perineural invasion imply aggressive behaviour of the prostate carcinoma (Hern andez & Thompson 2004; Humphrey 2004; Greene et al. 2009 ). Our study suggests that SOX11 promoter methylation may be used to predict aggressive behaviour of prostate cancer. Future studies are warranted to confirm our data in a larger independent cohort. In addition, validation with more sensitive techniques able to quantify methylation and further confirmation at the protein level are needed. It would be of importance to extend SOX11 studies to prostate biopsies, blood and urine samples, which potentially may aid in pre-operative diagnostics and risk stratification of prostate cancer.
In conclusion, our data indicate that SOX11 promoter methylation occurred frequently in prostate carcinoma tissues compared to BPH. Methylation of SOX11 correlated with higher PSA level, higher Gleason score and perineural invasion in the patients with prostate cancer. SOX11 can be a promising methylation marker candidate for the detection and monitoring of prostate cancer.
